左旋多巴/ 卡比多巴联合恩他卡朋治疗帕金森病的临床研究

目的:观察左旋多巴/卡比多巴联合恩他卡朋(levodopa/carbidopa combined with entacapone,LC+E)治疗帕金森病(Parkinson's disease,PD)的临床效果。方法:选择我院2013年1月~2014年6月收治的112例PD患者,随机分为两组。其中对照组52例采用左旋多巴/卡比多巴(LC)治疗,观察组60例采用左旋多巴/卡比多巴联合恩他卡朋(LC+E)治疗。观察并比较两组治疗前后帕金森病评分量表(Unified Parkinson's Disease Rating Scale,UPDRS)的评分变化情况。结果:与治疗前比较,治疗后两组UPDRS-II日常生活能力评分,UPDRS-III运动能力评分显著下降,而UPDRS-VI SCHWABENGLAND日常活动能力评分显著上升,差异有统计学意义(P0.05);观察组各项变化情况比对照组明显,差异有统计学意义(P0.05)。两组UPDRS-I精神、行为、情绪和Hoehn与Yahr分级均无显著改善,差异无统计学意义(P0.05)。结论:左旋多巴/卡比多巴联合恩他卡朋可明显缓解PD症状,疗效优于左旋多巴/卡比多巴治疗,且安全性高,值得临床推广。

A Clinical Study of Levodopa/carbidopa Combined with Entacapone in Parkinson's Disease

Objective:To investigate the clinical effect of levodopa/carbidopa combined with entacapone (LC+E) in the treatment of Parkinson''s disease (PD).Methods:112 patients with PD who were treated in our hospital from January 2013 to June 2014 were selected and randomly divided into two groups. The patients in the control group (n=52) were treated with levodopa/carbidopa (LC), while the patients in the observation group (n=60) were treated with levodopa/carbidopa combined with entacapone (LC+E). Then the changes ofUnified Parkinson''sDisease RatingScale (UPDRS) inthe twogroups were observedand comparedbefore and after the treatment.Results:After treatment, UPDRS-II of ability of daily life, UPDRS-III of motion examination and UPDRS-IV of complications in the two groups significantly decreased, and UPDRS-VI of SCHWAB&ENGLAND scale of the ability of daily life increased (P<0.05); The changes of the observation group were significantly than those of the control group, and the differences were statistically significant (P<0.05). There was no significant difference about the UPDRS-I of mental, behavioral and emotional and UPDRS-V of the modify Hoehn and Yahr classification between the two groups (P>0.05).Conclusion:LC+E can significantly relieve the symptoms of PD, which is much better than that in LC. And, it has a higher safety. It is worth the clinical promotion.